SCHEMBL162227

SCHEMBL162227

CN[C@H](C(=O)O)C(C)(C)S

nearest known ligand 0.46

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.46
PTGS1 P23219 1/20 0.46
ANPEP P15144 1/20 0.30
ENPEP Q07075 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18095145 1.00 ALDH1A1 (0.46) ALDH1A1MAPTPTGS1ANPEPENPEP
SCHEMBL18095144 1.00 ALDH1A1 (0.46) ALDH1A1MAPTPTGS1ANPEPENPEP
SCHEMBL8827780 0.84 ALDH1A1 (0.35) ALDH1A1MAPTPTGS1
SCHEMBL6866649 0.80 ALDH1A1 (0.36) ALDH1A1MAPTPTGS1
SCHEMBL3458099 0.79 CA2 (0.37) ALDH1A1MAPTPTGS1
SCHEMBL3458098 0.79 CA2 (0.37) ALDH1A1MAPTPTGS1
SCHEMBL88565 0.79 CA2 (0.37) ALDH1A1MAPTPTGS1
SCHEMBL31668698 0.78 ALDH1A1 (0.44) ALDH1A1MAPTPTGS1
SCHEMBL7717432 0.78 ALDH1A1 (0.44) ALDH1A1MAPTPTGS1
SCHEMBL30125226 0.78 ALDH1A1 (0.44) ALDH1A1MAPTPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-05-21 US disclosed
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE ENTERA BIO LTD. (IL) 2026-05-07 US disclosed
WO-2026085582-A1 PROTEIN CAGES THE UNIVERSITY OF SYDNEY (AU) 2026-04-30 WO disclosed
EP-4731266-A1 NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES The Regents of the University of Michigan (US) 2026-04-29 EP disclosed
US-20260109870-A1 PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-04-23 US disclosed
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2026-04-23 US disclosed
US-12605425-B2 TNF muteins and uses thereof OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2026-04-21 US disclosed
EP-4710935-A2 NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF Aravax Pty Ltd (AU) 2026-03-18 EP disclosed
US-12576191-B2 Method of inducing cardiomyocytes proliferation and treating heart diseases YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2026-03-17 US disclosed
WO-1997016202-A1 CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER AMRAD OPERATIONS PTY. LTD. (AU) 1997-05-09 WO disclosed
WO-1997015663-A1 A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-05-01 WO disclosed
WO-1997012037-A1 A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-04-03 WO disclosed
WO-1997005257-A1 PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1997-02-13 WO disclosed
WO-1997004091-A1 NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-02-06 WO disclosed
EP-0745092-A1 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1996-12-04 EP disclosed
EP-0672049-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1995-09-20 EP disclosed
WO-1994028014-A2 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1994-12-08 WO disclosed
WO-1994011388-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1994-05-26 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE PTH1R, FGF23, PTMS ALDH1A1 2763/4885MAPT 1107/4885PTGS1 1998/4885
US-12605425-B2 TNF muteins and uses thereof TNFRSF1A, TNF, TNFSF11 ALDH1A1 4618/4885MAPT 899/4885PTGS1 445/4885
US-20260109870-A1 PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME NONO, NGLY1, PTMS ALDH1A1 4370/4885MAPT 381/4885PTGS1 4045/4885
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS FCGR3B, FCGR1A, FCGR2A ALDH1A1 3922/4885MAPT 1974/4885PTGS1 3035/4885
US-12576191-B2 Method of inducing cardiomyocytes proliferation and treating heart diseases MYLK2, TNNI3, MYL6 ALDH1A1 4773/4885MAPT 4156/4885PTGS1 3790/4885
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION CTSL, CPA4, ACE2 ALDH1A1 1754/4885MAPT 3052/4885PTGS1 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.